Table 2. Percentage of Patients Who Had All, Some, or No Viral Loads Suppressed During 12 Months of Observation, by Demographic and Clinical Subgroups, 2012–2013*.
| Subgroups | All Viral Load Results Suppressed, % (n) | Some Viral Load Results Suppressed, % (n) | No Viral Load Results Suppressed, % (n) | χ2 Result (P) |
|---|---|---|---|---|
| Sex† | ||||
| Female (n = 2973) | 60.7 (1805) | 27.9 (831) | 11.3 (337) | 49.27 (<0.001) |
| Male (n = 7896) | 67.8 (5350) | 23.7 (1873) | 8.5 (673) | |
| Age at the time of entry in cohort, yr | ||||
| 18–39 (n = 2147) | 52.2 (1120) | 32.6 (699) | 15.3 (328) | 286.83 (<0.001) |
| 40–49 (n = 2830) | 64.8 (1834) | 24.8 (702) | 10.4 (294) | |
| 50–91 (n = 5894) | 71.3 (4201) | 22.1 (1304) | 6.6 (389) | |
| Race/ethnicity | ||||
| White non-Hispanic (n = 3766) | 68.3 (2571) | 24.4 (918) | 7.4 (277) | 113.35 (<0.001) |
| Black non-Hispanic (n = 4229) | 61.1 (2584) | 26.2 (1109) | 12.7 (536) | |
| Hispanic (n = 2537) | 69.0 (1751) | 23.9 (606) | 7.1 (180) | |
| Other (n = 291) | 71.5 (208) | 23.0 (67) | 5.5 (16) | |
| HIV acquisition (exposure) risk category | ||||
| Heterosexual (n = 4611) | 62.5 (2881) | 26.9 (1242) | 10.6 (488) | |
| MSM (n = 4355) | 70.6 (3077) | 22.0 (959) | 7.3 (319) | 79.60 (<0.001) |
| MSM + IDU (n = 614) | 64.0 (393) | 25.4 (156) | 10.6 (65) | |
| IDU (n = 591) | 62.1 (367) | 28.1 (166) | 9.8 (58) | |
| Undetermined/unknown/other/missing (n = 702)‡ | 62.4 (438) | 25.9 (182) | 11.7 (82) | |
| Recency of testing HIV positive (from the time of entry viral load), mo | ||||
| <3 (n = 1042) | 45.4 (473) | 41.1 (428) | 13.5 (141) | |
| 3–12 (n = 382) | 47.1 (180) | 39.5 (151) | 13.4 (51) | 287.78 (<0.001) |
| 13–24 (n = 516) | 71.5 (369) | 20.2 (104) | 8.3 (43) | |
| 25–48 (n = 1053) | 66.1 (696) | 23.5 (248) | 10.4 (109) | |
| 49+ (n = 7880) | 69.0 (5438) | 22.5 (1774) | 8.5 (668) | |
| No. viral load results during observation | ||||
| 2 (n = 2723) | 71.8 (1954) | 13.4 (365) | 14.8 (404) | |
| 3 (n = 3765) | 73.9 (2782) | 18.5 (697) | 7.6 (286) | 913.16 (<0.001) |
| 4 (n = 2646) | 65.0 (1720) | 28.5 (755) | 6.5 (171) | |
| 5 (n = 1019) | 47.4 (483) | 43.8 (446) | 8.8 (90) | |
| 6–10 (n = 720) | 30.1 (217) | 61.4 (442) | 8.5 (61) | |
| Missed scheduled HIV primary care visit§ | ||||
| 0 (n = 7642) | 71.5 (5461) | 21.5 (1644) | 7.0 (537) | |
| 1 (n = 2517) | 56.2 (1415) | 30.3 (763) | 13.5 (339) | 438.32 (<0.001) |
| 2 (n = 591) | 42.5 (251) | 38.8 (229) | 18.8 (111) | |
| 3+ (n = 123) | 23.6 (29) | 56.1 (69) | 20.3 (25) | |
| CD4 count at the time of entry in cohort, cells/μL | ||||
| <200 (n = 1448) | 29.3 (424) | 44.3 (641) | 26.4 (383) | 1297.34 (<0.001) |
| 200–500 (n = 4208) | 62.9 (2649) | 27.9 (1176) | 9.1 (383) | |
| >500 (n = 5216) | 78.3 (4083) | 17.0 (888) | 4.7 (245) | |
| Clinic | ||||
| A (n = 1333) | 53.1 (708) | 38.6 (514) | 8.3 (111) | |
| B (n = 1096) | 70.4 (771) | 22.3 (244) | 7.4 (81) | |
| C (n = 2064) | 73.0 (1507) | 20.2 (416) | 6.8 (141) | 337.75 (<0.001) |
| D (n = 1607) | 74.1 (1190) | 18.9 (304) | 7.0 (113) | |
| E (n = 1108) | 71.9 (797) | 20.1 (223) | 7.9 (88) | |
| F (n = 3665) | 59.6 (2183) | 27.4 (1004) | 13.0 (478) |
Some variables have a few cases of missing data.
*
Cohort patients had at least 2 viral load tests during 12 months of observation.
†
The 69 transgender patients were not included as a separate subgroup because of small numbers, and they were not included in the denominators of the other stratification variables in this table.
‡
The HIV acquisition (exposure) variable included 170 cases of missing data.
§
No-show without prior cancellation during 12-month observation period.